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NEWS & Views 
New update on the management of axial Spondyloarthritis: Time to stop the split ten 
years on. 
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Main text 
The American College of Rheumatology (ACR), Spondylitis Association of America (SAA), and 
Spondyloarthritis Research and Treatment Network (SPARTAN) have published a new update of 
their recommendations for the treatment of axial spondyloarthritis. Highlights include the 
incorporation of newly available therapies, favouring a treatment strategy based on physician 
assessment rather than a treat-to-target approach and the use of imaging to aid disease monitoring. 
However, the guidelines artificially refer to the individual non-radiographic and radiographic 
disease groups rather than to a unified entity.   
The recognition of axial spondyloarthritis (axSpA) as a wider entity than ankylosing spondylitis (AS), 
also known as radiographic axial spondyloarthritis (r-axSpA), was significantly aid by the publication 
of the classification criteria by the Assessment in Spondyloarthritis Society (ASAS) in 20091. The 
contribution of these beyond the older ESSG or Amor criteria, was the recognition that unequivocal 
radiographic sacroiliitis, a key criterion in the modified New York criteria to define AS, is a late feature 
in the disease course; and that earlier disease stages may be identified by other imaging methods, 
chiefly MRI or a combination of key inflammatory findings such as an elevated CRP and/or associated 
disease features including HLA-B27. As opposed to other chronic disorders such as rheumatoid 
arthritis or lupus, widely accepted to have a varied clinical spectrum where a subset of patients may 
have a more benign or even self-limiting course, controversy is still rife as to whether earlier, non-
radiographic stages in axSpA do indeed represent part of the same disease spectrum. This dispute is 
rooted in the absence of specific antibodies or validated biomarkers of disease which has resulted in 
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the artificial use of radiographic sacroiliitis as the main biomarker to identify axSpA, a problem further 
compounded by the well-known ﾉ;Iﾆ ﾗa ヴWﾉｷ;Hｷﾉｷデ┞ ﾗﾐ デｴW ﾗヮWヴ;デﾗヴげゲ ｷﾐデWヴヮヴWデ;デｷﾗﾐ ﾗa ヴ;Sｷﾗｪヴ;ヮｴｷI 
sacroiliitis2 . Ten years on, the new ACR/SAA/SPARTAN3 recommendations still outline AS and nr-axSpA 
as two separate diseases with individual yet similar recommendations for each. Mounting evidence 
however, unveils same levels of disease activity, comorbidities and treatment response4 for nr and r-
axSpA proving that their management might have to be as intensive, regardless of its classification.  
 
The updated ACR/SAA/SPARTAN document retains non-steroidal anti-inflammatory drugs (NSAIDs) as 
the first-line treatment together with physical therapy. A continuous treatment rather than さon 
demandざ is preferred both in the non-radiographic and radiographic stages, especially if the disease 
is active. If NSAIDs fail to provide adequate disease control, biologics should then be considered. TNF 
inhibitors (TNFi) are the preferred first option over IL-17 inhibitors as also outlined in the most recent 
2016 ASAS-EULAR recommendations5. TNFi are also preferred in the presence of extra-articular 
manifestations such as uveitis, which can occur across the axSpA spectrum.  Tofactinib, a JAk inhibitors 
currently under phase III trials, is also mentioned as an alternative although more data are needed to 
position it. Switching to IL-17 inhibitors is recommended if primary non-response to TNFi ocurrs, whilst 
cycling to a different TNFi is encouraged in case of secondary non-response. Overall, the advocacy for 
TNFi is sustained by a longer clinical experience rather than a proven superiority over IL-17 inhibitors. 
Added to that, real-world data are lacking on switching between treatment targets and solid 
knowledge on the immune-pathotype that may allow for treatment stratification remains elusive.  
 
With the introduction of biosimilars, leading to the availability of substantially cheaper TNFi, the 
economic burden attached to biologic therapies has become a real consideration for rheumatologists 
at the time of prescribing.  Ward et al3, have conditionally recommended against switching from the 
originator TNFi to its biosimilar in patients with stable AS. This recommendation however has different 
implications depending on individual local guidelines and funding sources and cannot be extrapolated 
worldwide. Since several countries have pushed for switching to the TNFi biosimilar when possible, 
their experience will provide valuable data on its real-world interchangeability6.  
 
There are some stark differences between the latest ACR/SAA/SPARTAN update and ASAS-EULAR 
recommendations. Interestingly, the North American panel conditionally recommends against using a 
treat-to-target strategy based on the Ankylosing Spondylitis Disease Activity Score (ASDAS), which is 
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in contrast with the European recommendations5. The rationale behind this is the lack of hefty 
evidence showing the potential impact of a treat-to-target strategy on slowing radiographic 
progression and the risk of rapid turnaround in treatments, exhausting all available options in some 
patients. Although there is a recommendation on quantifying disease activity to inform treatment 
decisions, no outcome is proposed. The development of robust outcome measures in axSpA remains 
on the research agenda since available tools rely significantly on subjective measures. Importantly, it 
remains to be demonstrated whether the absence of a defined target might risk undertreatment in 
some cases.  
 
Drug tapering has also been addressed in the 2019 ACR/SAA/SPARTAN update with a 
recommendation against tapering of the biologic dose as opposed to the ASAS-EULAR document 
where tapering was also considered and recommended. Despite literature being scarce in this field, 
successful tapering without significant relapses has been reported7. As more patients with axSpA are 
receiving biologic treatment and early intervention is encouraged, long term impact of continuous 
biologic therapy needs to be explored. In the absence of data driven definitions of remission and flare, 
benefits and risks of tapering have to be balanced and ultimately discussed with the patient as outlined 
on the 2019 ACR update. 
 
Finally, a novelty from the 2019 ACR/SAA/SPARTAN recommendations is their advocacy for the use of 
magnetic resonance imaging (MRI) in patients receiving biologics where the activity of the disease is 
unclear and where this information would influence treatment decisions. MRI can identify active 
inflammation that will respond better to treatment8 and may lead to disease progression9. However, 
the authors rightly warn about the limitations of MRI in disease monitoring particularly in view of the 
limited knowledge on correlation between MRI lesions and treatment response, or the significance of 
sub-clinical inflammatory change. Furthermore, to date, no therapies have proven to be disease 
modifiers in axial SpA, with only limited data showing potential effects from NSAIDS, TNFi and IL-17 
inhibitors on slowing structural damage. Larger, longitudinal trials are needed to address this question. 
 
In conclusion, the 2019 ACR/SAA/SPARTAN recommendations update the rheumatology community 
with useful advice on the use of new therapies and their management. Despite being formulated at 
addressing two distinct disease subsets: radiographic (AS) and non-radiographic, the similarities in the 
available evidence highlight them as part of the same clinical entity. The integration of MRI in the 
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evaluation of axSpA may be of value in some cases.   Research efforts are needed to identify potential 
biomarkers and immune-phenotypes that may guide informed treatment stratification and overall 
understanding of axSpA10.  
 
 
Box. Highlights of the 2019 ACR/SAA/SPARTAN recommendations 
 Continuous treatment with NSAIDS together with physical therapy is the preferred first-line 
of management in axial spondyloarthritis.  
 If NSAIDS fail, biologics should be considered with a predilection for TNF inhibitors (TNFi) as 
a first option.  
 IL-17 inhibitors are recommended when patients present a primary non-response to TNFi. 
 TNFi monoclonal antibodies are preferred for treating axial spondyloarthritis with recurrent 
uveitis or inflammatory bowel disease.  
 A treatment strategy based on physician assessment is suggested as opposed to a treat-to-
target strategy.  
 When the activity of the disease is unclear, magnetic resonance of the sacroiliac joints and 
spine can be helpful.  
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